1,323 reports of this reaction
3.6% of all AXITINIB reports
#4 most reported adverse reaction
NEOPLASM PROGRESSION is the #4 most commonly reported adverse reaction for AXITINIB, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 1,323 FDA adverse event reports linking AXITINIB to NEOPLASM PROGRESSION. This represents approximately 3.6% of all 37,114 adverse event reports for this drug.
Patients taking AXITINIB who experience neoplasm progression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEOPLASM PROGRESSION is moderately reported among AXITINIB users, representing a notable but not dominant share of adverse events.
In addition to neoplasm progression, the following adverse reactions have been reported for AXITINIB:
The following drugs have also been linked to neoplasm progression in FDA adverse event reports:
NEOPLASM PROGRESSION has been reported as an adverse event in 1,323 FDA reports for AXITINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEOPLASM PROGRESSION accounts for approximately 3.6% of all adverse event reports for AXITINIB, making it a notable side effect.
If you experience neoplasm progression while taking AXITINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.